PubRank

Chemoimmunotherapy with oral low-dose fludarabine, cyclophosphamide and rituximab (old-FCR) as treatment for elderly patients with chronic lymphocytic leukaemia.

PubWeight™: 0.78‹?›

🔗 View Article (PMID 24934847)

Published in Leuk Res on June 02, 2014

Authors

Alessandro Gozzetti1, Veronica Candi2, Alberto Fabbri2, Luana Schiattone2, Emanuele Cencini2, Francesco Lauria2, Adele Frasconi2, Rosaria Crupi2, Donatella Raspadori2, Giulia Papini2, Marzia Defina2, Giulia Bartalucci2, Monica Bocchia2

Author Affiliations

1: Hematology, Azienda Ospedaliera Universitaria, Siena, Italy. Electronic address: gozzetti@unisi.it.
2: Hematology, Azienda Ospedaliera Universitaria, Siena, Italy.

Articles citing this ↘

Therapeutic potential of new B cell-targeted agents in the treatment of elderly and unfit patients with chronic lymphocytic leukemia. J Hematol Oncol (2015) 0.89

Effects of survivin on FVADT chemotherapy for refractory multiple myeloma. Exp Ther Med (2016) 0.75